



BioLight Life Sciences Ltd.

(the "Company")

July 28, 2024

To: Israel Security Authority
www.isa.gov.il

TASE Tel Aviv Stock Exchange
www.tase.co.il

Re: Immediate Report

BioLight [TASE:BOLT] hereby announces that, further to BioLight's immediate report dated April 18, 2024, regarding the receipt by its subsidiary DiagnosTear Ltd. ("**DiagnosTear**") of results of a large clinical trial in India to test its TeaRTM product that is planned to become a tool for Point-of-Care diagnosis and analysis of Dry Eye Syndrome (DES), by quantifying 5 protein biomarkers in the tear fluid (the "**Product**"), as part of a cooperation agreement signed with an international pharmaceutical company and a leading ophthalmic medical center in India, for the purpose of examining commercial cooperation between DiagnosTear and the international pharmaceutical company, and as stated in Section 1 of the events report attached in Section 9.4 of BioLight's shelf prospectus, DiagnosTear has been informed by the international pharmaceutical company that it will not exercise its right to negotiate a license agreement due to a lack of business synergy.

As informed, DiagnosTear is in negotiations with distributors to enter into distribution agreements regarding distributing the Product in certain countries in Europe, the Far East, and Israel. It should be noted that there is no certainty that Diagnostear's aforementioned actions will culminate in binding distribution agreements.

Forward-Looking Statement - *The information, details, and assessments of BioLight and DiagnosTear included in this report regarding the negotiating to engage with distributors in various countries and the possibility of maturing into a memorandum of understanding and/or a binding agreement and the final terms that will be determined within the framework of a binding agreement (if at all), are "forward-looking information" as defined in the Israeli Securities Law, 1968, which is subject to high uncertainty, and is based, among other things, on third-party factors and many variables that BioLight and DiagnosTear do not necessarily have control over, and therefore, it is possible that the information, details, and assessments mentioned may not materialize and/or may not materialize in full and/or may materialize in a manner significantly different from what was initially assessed or anticipated.*

Free translation: non-binding

This is a translated version of the Company's immediate report in Hebrew as filed with the Israeli SEC - created for convenience purposes only. In case of contradiction, the Hebrew version will prevail.